Notice of Results

Oxford Biomedica PLC
04 March 2005


FOR IMMEDIATE RELEASE                                              4 MARCH 2005


             OXFORD BIOMEDICA: NOTICE OF FY2004 PRELIMINARY RESULTS

Oxford, UK - 4 March 2005: Oxford BioMedica (LSE:OXB.L), the leading gene
therapy company, announces that it will be releasing its preliminary results for
the twelve months ended 31 December 2004 on Monday, 21 March 2005.

Meetings:

An analyst briefing will be held at 10:00 am on the day followed by a press
briefing which will commence at 11:30 am. The venue for both meetings will be
Buchanan Communications, 107 Cheapside, London EC2V 6DN.

Web cast:

Simultaneously to the analyst briefing at 10.00 am, there will be a live audio
web cast of the results presentation.

To connect to the web cast facility, please go to the Company's website: http://
www.oxfordbiomedica.co.uk/ approximately 10 minutes (09:50 am) before the start
of the briefing. This will also be available for replay shortly after the
presentation.

-Ends-


For further information, please contact:
Oxford BioMedica plc:
Professor Alan Kingsman, Chief Executive                Tel: [phone]
Andrew Wood, Chief Financial Officer

City/Financial Enquiries:
Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan   Tel: [phone]
Communications

Scientific/Trade Press Enquiries:
Sue Charles/ Katja Stout/ Ashley Lilly                  Tel: [phone]
Northbank Communications

Notes to editors

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development of novel gene-based therapeutics with a focus on the areas of
oncology and neurotherapy. The Company was established in 1995 as a spin out
from Oxford University, and is listed on the London Stock Exchange.

Oxford BioMedica has core expertise in gene delivery, as well as in-house
clinical, regulatory and manufacturing know-how. In oncology, the pipeline
includes an immunotherapy and a gene therapy in multiple Phase II trials, and a
preclinical targeted antibody therapy in collaboration with Wyeth. In
neurotherapy, the Company's lead product is a gene therapy for Parkinson's
disease, which is expected to enter clinical development in 2005, and four
further preclinical candidates. The Company is underpinned by over 80 patent
families, which represent one of the broadest patent estates in the field.

The Company has a staff of approximately 65 split between its main facilities in
Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California.
Oxford BioMedica has corporate collaborations with Wyeth, Intervet, Amersham,
Viragen, MolMed and Kiadis; and has licensed technology to a number of companies
including Merck & Co and Biogen Idec.

Further information is available at www.oxfordbiomedica.co.uk.

                      This information is provided by RNS
            The company news service from the London Stock Exchange